AXGNAxogen, Inc.
$36.13+110% 1Y
$36.13
$15.5952 weeks$51.57
AXGN in its own filings
AXGN's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
400
Events found in the filings · across 1,366 filings · the record starts in 1995
- Hard flags
- 2
Hard flags
- Most recent filing
- Oct 1, 2026
Most recent filing · Form 8-K
- Record starts
- May 12, 1995
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Oct 28, 2026
- Change in certifying accountant2 occurrences
- 2018-03-13
- Late periodic report7 occurrences
- 2011-05-17
- SEC comment-letter activity27 occurrences
- 2024-04-26
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair.Regulation FD disclosure · press release
- Sep 10, 2026The information contained in.Material agreement entered · Form 8-K/A
- Sep 10, 2026Merger Agreement On September 9, 2026, Axogen, Inc., a Minnesota corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Omega Merger Sub, Inc., a Georgia corporation and wholly owned subsidiary of the Company (“Merger Sub”), BioCircuit Technologies, Inc., a Georgia …Material agreement entered · Form 8-K
- Jul 29, 2026Axogen, Inc. Reports Second Quarter 2026 Financial Results.Earnings release · press release
- Jan 23, 2026On January 21, 2026, Axogen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Wells Fargo Securities, LLC and Mizuho Securities USA LLC, as representatives of the underwriters (the “Underwriters”)Material agreement entered · Form 8-K
- Dec 5, 2025On December 3, 2025, the Compensation Committee of the Board of Directors of Axogen, Inc. (the “Company”) approved amendments to the compensation arrangements for Lindsey Hartley, the Company’s Chief Financial Officer.Director or officer change · Form 8-K
- Dec 4, 2025On December 3, 2025, the Company announced it received FDA approval of its Biologics License Application for Avance ® (acellular nerve allograft-arwx)Regulation FD disclosure · Form 8-K
- Oct 29, 2025Axogen, Inc. Reports Third Quarter 2025 Financial Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…